Update on bluebird bio's HGB-205 study at Cooley's Anemia Foundation Symposium

US biotech start-up bluebird bio (Nasdaq: BLUE) announced that Marina Cavazzana, professor of hematology and director of the Department of Biotherapy at Hospital Necker, University Paris Descartes, France, and lead investigator for the HGB-205 clinical study, presented a review of the clinical study experience with lentiviral-based gene therapies for beta-thalassemia at the 10th Annual Cooley’s Anemia Foundation Symposium in Chicago, USA.

Prof Cavazzana summarized results from HGB-205, an ongoing clinical study using LentiGlobin BB305 for the treatment of beta-thalassemia major and severe sickle cell disease, which were presented earlier this year at the Annual Congress of the European Hematology Association. She also provided an update on subject 1003, a patient with beta-thalassemia major treated by Prof Cavazzana in 2007 in the LG001 study using the first-generation HPV569 lentiviral vector.

Patient setback reported